tbuckley/cabot-search huggingface dataset:
EXPERIENCIA EN COLANGIOPANCREATOGRAFÍA RETRÓGRADA ENDOSCÓPICA (CPRE) EN PACIENTES TRASPLANTADOS HEPÁTICOS
Authors: R Jijón Crespín, F Alberca De Las Parras, J Egea Valenzuela, A Serrano Jiménez, B García Pérez, JA Pons Miñano, G Carrilero Zaragoza, P Tomás Pujante, E Iglesias Jorquera, F Carballo Álvarez
Journal: Endoscopy (2016)

Introducción: La mayoría de las estenosis en pacientes trasplantados se diagnostican entre 1 y 3 meses postrasplante. Se dividen en anastomóticas y no anastomóticas. Son las primeras las que tienen principal indicación de terapia endoscópica de primera intención.
Complete Remission Status at Autologous Transplantation Is an Important Prognostic Factor in Multiple Myeloma Patients Received Upfront Single Autologous Transplantation.
Authors: Jin Seok Kim, June-Won Cheong, Yoo-Hong Min, Cheolwon Suh, Hawk Kim, Deog Yeon Jo, Hun Mo Ryoo, Kihyun Kim, Sung Soo Yoon, Jae Hoon Lee
Journal: Blood (2007)
Effect of Comedication With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study
Authors: A. Sepriano, S. Ramiro, D. van der Heijde, P. Ávila‐Ribeiro, R. Fonseca, J. Borges, L. Teixeira, P. D. Carvalho, M. Cerqueira, J. Neves, T. Meirinhos, A. Barcelos, G. Sequeira, M. J. Salvador, J. Canas da Silva, H. Santos, M. Bernardes, E. Vieira‐Sousa, H. Canhão, J. C. Branco, F. Pimentel‐Santos, R. Landewé
Journal: Arthritis & Rheumatology (2016)

Objective To evaluate whether use of comedication with conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) influences the retention of tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA). Methods Patients with SpA from the Rheumatic Diseases Portuguese Register who started treatment with their first TNFi between 2001 and 2014 were included in this study. Cox regression analysis was used to estimate the effect of comedication with csDMARDs on TNFi retention in 2 types of models: a model in which baseline (time‐fixed) variables were included, and a second model incorporating time‐varying variables, including sociodemographic features, measures of disease activity, measures of physical function, and cotreatment with other drugs (nonsteroidal antiinflammatory drugs and oral steroids). To control for possible confounding by indication, the effect of csDMARD comedication on TNFi retention was also tested after adjustment for the treatment propensity score. Results In total, 954 patients were included in the study, of whom 289 (30.3%) discontinued treatment with their first TNFi after a median follow‐up time of 2.5 years (range 0.08–13 years). Inefficacy was the most common reason for TNFi discontinuation (55.7% of patients). In the multivariable analyses, comedication with csDMARDs had no measurable effect on TNFi retention, neither in the baseline model (hazard ratio [HR] 0.83, 95% confidence interval [95% CI] 0.59–1.16) nor during follow‐up in the model adjusted for time‐varying covariates (HR 1.07, 95% CI 0.68–1.68). The effect of csDMARD comedication remained nonsignificant after propensity score adjustment. Conclusion Comedication with csDMARDs does not prolong TNFi retention in patients with SpA in clinical practice, suggesting that there is no benefit conferred by the concomitant use of these drugs.
Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial.
Authors: Amit K Jain, Sonia Kumar, Gavin S. Choy, Desiree Hollemon, Elizabeth Ann Mittendorf
Journal: Journal of Clinical Oncology (2015)

e11609 Background: Current therapies targeting HER2 neuprotein expression are effective for breast tumors (CaB) with high expression levels (IHC 3+). However, most breast tumours exhibit low to intermediate expression of HER2 (IHC 1+/2+). Nelipepimut-S (NeuVax; Galena Biopharma) is a cancer vaccine that generates a specific immune response to E75, a HER2 peptide. The ongoing Phase 3 trial (PRESENT) is evaluating NeuVax to prevent CaB recurrence in HER2 low or intermediate patients. Given the importance of identifying eligible patients, the Bond Oracle HER2 IHC System (Leica Biosystems) is currently being validated to reliably discriminate IHC HER2 0, 1+, and 2+, expression levels by correlating to independent analytical measures of HER2 expression Methods: HER2 receptor load was determined via flow cytometry for three immortalized CaB cell lines with various levels of HER2 expression (MDA-MB-453 [2+], MDA-MB-175 [1+], and MDA-MB-231 [0]). In parallel, FFPE cell blocks were generated for each cell line and sectioned for HER2 IHC. Quantitative Western Blots was performed to measure HER2 protein quantity. The measured receptor loads and quantitation by Western Blots were correlated to HER2 IHC scores of 0, 1+, and 2+. Results: See Table. Conclusions: These data demonstrate a direct correlation between cell line receptor load, quantitative measure of HER2 protein, and IHC score. The ability to discriminate HER2 protein expression at the low and intermediate levels in CaB will identify patients for new treatments in development such as NeuVax. Specifically, the validation of the Bond Oracle HER2 IHC System to distinguish IHC 0, 1+, and 2+ expressions supports its use as a companion diagnostic. Analytical data demonstrating correlation of IHC results with HER2 receptor load and quantitative measurement of HER2 protein. Cell line Bond Oracle HER2 expression by IHC HER2 receptor load per cell by Flow Cytometry (x104 ) HER2 protein measurement by Quantitative Western Blot (Chemiluminescence) x104 MDA-MB-453 2+ 9.0 5.8 MDA-MB-175 1+ 5.4 2.7 MDA-MB-231 0 0.8 0.7
Impact of Thrombophilia and Incidence of Symptomatic Thromboembolism in First Degree Family Members (FM) of Pediatric Index Cases: a Prospective Cohort Study in FM &gt; 14 Years of Age.
Authors: Ulrike Nowak-Gottl, Monika Stoll, Rolf Mesters, Sabine Thedieck, Susan Halimeh, Christine Heller, Karin Kurnik, Neil A Goldenberg, Susanne Holzhauer
Journal: Blood (2009)
The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
Authors: Franck E. Nicolini, Grzegorz W. Basak, Dong-Wook Kim, Eduardo Olavarria, Javier Pinilla-Ibarz, Jane F. Apperley, Timothy P. Hughes, Dietger Niederwieser, Michael J. Mauro, Charles Chuah, Andreas Hochhaus, Giovanni Martinelli, Maral DerSarkissian, Andrew Kageleiry, Mo Yang, Hui Huang, Lisa J. McGarry, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood (2015)
Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.
Authors: Andrew L. Feldman, David X. Sun, Mark E. Law, Anne J. Novak, Ayoma D. Attygalle, Erik C. Thorland, Stephanie R. Fink, Julie A. Vrana, B. Lynn Caron, William G. Morice, Ellen D. Remstein, Karen L. Grogg, Paul J. Kurtin, William R. Macon, Ahmet Dogan
Journal: Blood (2007)
TCT-489 Impact of Left Ventricular Hypertrophy on Coronary Artery Spasm as assessed by Acetylcholine Provocation Test
Authors: Woo Hyeun Kim, Seung-Woon Rha, Byoung Geol Choi, Jae Kyeong Byun, Se Yeon Choi, Jun Hyuk Kang, Ja Yeon Choi, James Hall, Sung Hun Park, SunKi Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
TCT-244 Lower rates of repeat revascularization among patients with prior coronary artery bypass grafting is partly due to lack of adequate target vessels
Authors: Anirudh Kumar, John Wagener, Schuyler Jones, Daniel Wojdyla, Manesh Patel, Samuel Horr, Samir Kapadia, Sunil Rao
Journal: Journal of the American College of Cardiology (2016)
COLEDOCODUODENOSTOMÍA POR ECOENDOSCOPIA: ESTUDIO COMPARATIVO DE EFICACIA Y SEGURIDAD ENTRE PRÓTESIS METÁLICAS CILÍNDRICAS Y DE APOSICIÓN LUMINAL
Authors: C De La Serna Higuera, I Peñas, M De Benito, R Sanchez, P Diez, V Busto, P Gil, M Perez-Miranda
Journal: Endoscopy (2016)

Introducción y Objetivos: El drenaje por ecoendoscopia es el tratamiento de elección de la ictericia obstructiva maligna (IOM) tras CPRE fallida/no factible. La coledoco-duodenostomía (CD) con prótesis metálicas tubulares (PMT) garantiza intervalos prolongados de permeabilidad pero presenta limitaciones evitables mediante prótesis de aposición luminal (PMAL). Sin embargo su inserción resulta más compleja. Realizamos un estudio comparativo de viabilidad, seguridad y eficacia entre ambas técnicas.
P0952 : Transient hepatic overexpression of the insuline-like growth factor 2 (IGF2) induces lipid droplet formation
Authors: S.M. Kessler, S. Laggai, E. Van Wonterghem, R.E. Vandenbroucke, M. Ogris, C. Libert, A.K. Kiemer
Journal: Journal of Hepatology (2015)
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
Authors: Kazumoto Murata, Mai Asano, Akihiro Matsumoto, Masaya Sugiyama, Nao Nishida, Eiji Tanaka, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto, Takayoshi Shirasaki, Masao Honda, Shuichi Kaneko, Hiroyuki Gatanaga, Shinichi Oka, Yuki I Kawamura, Taeko Dohi, Yasutaka Shuno, Hideaki Yano, Masashi Mizokami
Journal: Gut (2016)

The clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and association with nucleos(t)ide (NUC) analogue administration.Serum IFN-λ3 level was measured in 254 patients with HBV with varying clinical conditions using our own high sensitivity method. The resulting values were compared with various clinical variables. In addition, cell lines originating from various organs were cultured with NUCs, and the production of IFN-λ3 was evaluated.Higher serum IFN-λ3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir). There were no other differences in the clinical background between the two groups. A rise in the serum IFN-λ3 levels was observed during additional administration of the nucleotide analogues. In vitro experiments showed that the nucleotide analogues directly and dose-dependently induced IFN-λ3 production only in colon cancer cells. Furthermore, the supernatant from cultured adefovir-treated colon cancer cells significantly induced IFN-stimulated genes (ISGs) and inhibited hepatitis B surface antigen (HBsAg) production in hepatoma cells, as compared with the supernatant from entecavir-treated cells.We discovered that the nucleotide analogues show an additional pharmacological effect by inducing IFN-λ3 production, which further induces ISGs and results in a reduction of HBsAg production. These findings provide novel insights for HBV treatment and suggest IFN-λ3 induction as a possible target.
TCT-154 Multivessel Revascularization versus Culprit Vessel Only Revascularization in Patients with ST-Elevation Myocardial Infarction and multivessel disease: An Updated Meta-analaysis
Authors: Poonam Velagapudi, Mohit Turagam, Natraj Katta, Mayank Mittal, Harsh Agrawal, Kul Aggarwal, J. Dawn Abbott
Journal: Journal of the American College of Cardiology (2016)
TCT-377 Safety of Ultra-Low Contrast Coronary Angiography in Patients with Advanced Chronic Kidney Disease
Authors: Navdeep Bhatti, Keyvan Karimi Galougahi, Tamim Nazif, Mark Hardy, David Cohen, Lloyd Ratner, Ajay Kirtane, Jeffrey Moses, Dimitri Karmpaliotis, Martin Leon, Ziad Ali
Journal: Journal of the American College of Cardiology (2016)
P0798 : The cost-effectiveness of sofosbuvir- and simeprevirbased therapies for HCV genotype 1 infection
Authors: B.P. Linas, J.R. Morgan, M.T. Pho, J.A. Leff, B.R. Schackman, S.A. Assoumou, J.A. Salomon, K.A. Freedberg, A.Y. Kim
Journal: Journal of Hepatology (2015)
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
Authors: David Stucki, Daniela Brites, Leïla Jeljeli, Mireia Coscolla, Qingyun Liu, Andrej Trauner, Lukas Fenner, Liliana Rutaihwa, Sonia Borrell, Tao Luo, Qian Gao, Midori Kato-Maeda, Marie Ballif, Matthias Egger, Rita Macedo, Helmi Mardassi, Milagros Moreno, Griselda Tudo Vilanova, Janet Fyfe, Maria Globan, Jackson Thomas, Frances Jamieson, Jennifer L Guthrie, Adwoa Asante-Poku, Dorothy Yeboah-Manu, Eddie Wampande, Willy Ssengooba, Moses Joloba, W Henry Boom, Indira Basu, James Bower, Margarida Saraiva, Sidra E G Vasconcellos, Philip Suffys, Anastasia Koch, Robert Wilkinson, Linda Gail-Bekker, Bijaya Malla, Serej D Ley, Hans-Peter Beck, Bouke C de Jong, Kadri Toit, Elisabeth Sanchez-Padilla, Maryline Bonnet, Ana Gil-Brusola, Matthias Frank, Veronique N Penlap Beng, Kathleen Eisenach, Issam Alani, Perpetual Wangui Ndung'u, Gunturu Revathi, Florian Gehre, Suriya Akter, Francine Ntoumi, Lynsey Stewart-Isherwood, Nyanda E Ntinginya, Andrea Rachow, Michael Hoelscher, Daniela Maria Cirillo, Girts Skenders, Sven Hoffner, Daiva Bakonyte, Petras Stakenas, Roland Diel, Valeriu Crudu, Olga Moldovan, Sahal Al-Hajoj, Larissa Otero, Francesca Barletta, E Jane Carter, Lameck Diero, Philip Supply, Iñaki Comas, Stefan Niemann, Sebastien Gagneux
Journal: Nature Genetics (2016)
TCT-571 Five year serial OCT follow-up of jailed side branches after treatment with ABSORB bioresorbable scaffolds
Authors: Valeria Paradies, George Vlachojannis, Kees-Jan Royaards, Floris Kauer, Jochem Wassing, Martin van der Ent, Pieter Smits
Journal: Journal of the American College of Cardiology (2016)
Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results
Authors: Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, April Dean, Sarah Conine, Heidi Sankala, John D. Roberts, Thomas C. Shea, Steven Grant
Journal: Blood (2014)
Effects of zoledronic acid on proliferation and synergy with cytotoxic agents in nasopharyngeal carcinoma cell lines
Authors: B.R. Ghimire, Zhang Li, Xing Zhang, Su Li, Xue Hou, Peijian Peng
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

2410 

Background: Recent evidence suggests that nitrogen-containing bisphosphonates (N-BPs) inhibits proliferation at clinically achievable concentrations and have shown the potential to become attractive agents for cancer therapy. Zoledronic acid (ZOL) is a new generation N-BP that has demonstrated the broadest clinical activity of all the available bisphosphonates. N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras. In addition, ZOL exerts synergistic antitumor activity when combined with other anticancer agents like cisplatin, taxoids, doxorubicin and imatinib. Although ZOL has exhibited antiproliferative and synergistic antitumor effects in different cells lines, effects on nasopharyngeal cancer (NPC) cell lines have never been reported.

Methods: In the first part of this study we investigated the antiproliferative effects of ZOL and cisplatin as single agents on four NPC cell lines CNE-1, CNE-2, SUNE-1 and 5-8F. Cell proliferation was determined by the MTT assay. NPC cell lines were seeded in a flat-bottomed 96-well plate at 10+4 in 200µl of medium per well and incubated with various concentrations of the test agents for 72 hours. IC50 values for each cell line were obtained using the non-linear regression program CalcuSyn. After an IC50 had been obtained the IC10 values for ZOL and cisplatin were calculated from the IC50 curve of each of the four cell lines. A total of 8x4 wells were seeded in a flat-bottomed 96-well plate at 10+4 cells in 200µl of medium per well, the first two rows were used as control, in the 3rd and 4th row, ZOL and cisplatin in combination were added , in the 5th and 6th rows ZOL and in the 7th and 8th rows cisplatin were added. In all the experiments, a concentration equivalent to IC10 for the particular cell lines was added . The entire plate was incubated for a total of 72 hours and the absorbance was measured at a wavelength of 540nm in a microplate reader.

Results: This study demonstrates that the third-generation N-BP, ZOL, has a direct antiproliferative effect and augments the effects of cisplatin against NPC cell lines as shown in Tables 1 and Tables 2.

Conclusion: ZOL has potent anti-NPC effects as a single agent in vitro, and augmented the effects of cisplatin. Thus, ZOL plus cisplatin may be a promising therapeutic strategy for NPC. The efficacy and safety of ZOL therapy for NPC should be verified in early phase clinical trials.
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial
Authors: Timo Mäkikallio, Niels R Holm, Mitchell Lindsay, Mark S Spence, Andrejs Erglis, Ian B A Menown, Thor Trovik, Markku Eskola, Hannu Romppanen, Thomas Kellerth, Jan Ravkilde, Lisette O Jensen, Gintaras Kalinauskas, Rikard B A Linder, Markku Pentikainen, Anders Hervold, Adrian Banning, Azfar Zaman, Jamen Cotton, Erlend Eriksen, Sulev Margus, Henrik T Sørensen, Per H Nielsen, Matti Niemelä, Kari Kervinen, Jens F Lassen, Michael Maeng, Keith Oldroyd, Geoff Berg, Simon J Walsh, Colm G Hanratty, Indulis Kumsars, Peteris Stradins, Terje K Steigen, Ole Fröbert, Alastair N J Graham, Petter C Endresen, Matthias Corbascio, Olli Kajander, Uday Trivedi, Juha Hartikainen, Vesa Anttila, David Hildick-Smith, Leif Thuesen, Evald H Christiansen
Journal: The Lancet (2016)
TCT-804 Improvement in the balloon pulmonary angioplasty strategy results in reduction of periprocedural complications and mortality rate
Authors: Arkadiusz Pietrasik, Szymon Darocha, Radosław Pietura, Anna Dobosiewicz, Justyna Norwa, Michał Piłka, Rafał Mańczak, Michał Florczyk, Adam Torbicki, Marcin Kurzyna
Journal: Journal of the American College of Cardiology (2016)
Comparison of Interferon Versus Thalidomide Versus RIC Allotransplant for Maintenance /Consolidation Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Single Center Experience.
Authors: Roland Fenk, Thorsten Graef, Ingmar Bruns, Leilani Ruf, Zohren Fabian, Ulrich Steidl, Ali-Nuri Huenerlituerkoglu, Rainer Haas, Guido Kobbe
Journal: Blood (2005)
TCT-692 Unilateral carotid artery occlusion is associated with higher stroke rate after TAVI
Authors: Jonathan Michel, Costanza Pellegrini, Tobias Rheude, Moritz von Scheidt, Teresa Trenkwalder, N. Patrick Mayr, Markus Kasel, Adnan Kastrati, Oliver Husser, Christian Hengstenberg
Journal: Journal of the American College of Cardiology (2016)
TCT-785 Association between the Platelet Reactivity under Clopidogrel Treatment and the Severity of Angioscopic Intra-stent Thrombus Following Drug-eluting Stent Implantation in the Femoropopliteal Artery
Authors: Takayuki Ishihara, Osamu Iida, Amane Kozuki, Toshiro Shinke, masashi fukunaga, Tetsuo Horimatsu, Kenichi Fujii, Junya Shite, Daisuke Terashita, yoshiro tsukiyama, Kan Zen, Mitsuyoshi Takahara, Masaaki Uematsu, Shinsuke Nanto
Journal: Journal of the American College of Cardiology (2016)
TCT-423 Adaptable strut contour analysis in scaffold evaluation by optical coherence tomography. Validation of the FANTOM II study analysis by micro-CT, bench test and in-vivo
Authors: Emil Holck, Jo Simonsen, Jouke Dijkstra, Jesper Thomsen, Annemarie Brüel, Jeffrey Anderson, Evald Christiansen, Niels Holm
Journal: Journal of the American College of Cardiology (2016)
Coexistence of Two Distinct Histological Subtypes of Follicular Lymphoma and Burkitt’s-Like Lymphoma in the Single Lymph Node: A Case Report and Literature Review.
Authors: Haruhisa Nagoshi, Kou Miyamoto, Fumiaki Sano, Aki Kyou, Yuji Nishio, Ikuo Miura, Junki Koike
Journal: Blood (2007)
4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass
Authors: Lung-Ji Chang, Lujia Dong, Jun Zhu, Zhitao Ying, Hao-Hsian Kuo, Yuchen Liu, Yu-Qin Song, Xiao-Pei Wang, Yong-Qian Jia, Ting Niu, Ting Liu, Ling Pan, Zhuo-Gang Liu, Tong Li, Ying-Chun Li, Kun Yao, Xiaoyan Ke, Hongmei Jing, Fang Bao
Journal: Blood (2015)
Immunological evaluation of personalized peptide vaccination with gemcitabine for advance pancreatic cancer patients
Authors: H. Yanagimoto, T. Mine, K. Yamamoto, S. Satoi, S. Honma, J. Mizoguchi, A. Yamada, M. Oka, Y. Kamiyama, K. Itoh, S. Takai
Journal: Journal of Clinical Oncology (2006)

14029 Background: A phase I clinical study was performed to determine safety and immunogenicity of personalized peptide vaccination with gemcitabine (GEM) in advanced pancreatic cancer patients (APC). Methods: Thirteen human histocompatibility leukocyte antigen (HLA)-A24+ or A2+ patients with unresectable (n=10) or recurrent (n=3) pancreatic cancer were treated with GEM plus up to four peptides that were positive for pre-vaccination measurement of peptide-specific IgG antibodies and/or cytotoxic T lymphocyte (CTL) precursors in the circulation (personalized peptide vaccine). GEM was administered at 1000mg/m 2 as a 30-min intravenous infusion once a week for three week, followed by 1 week of rest. All patients were treated on outpatient basis. The cycle was repeated every 8 weeks. Results: Peptide doses of vaccination per week were planned as follows: level 1, 1mg; level 2, 2mg; and level 3, 3mg. The main grade 3 toxicities observed during the first cycle in each level were neutropenia (15%), anemia (23%) and thrombocytopenia (15%). No significant differences in the toxicities were found between each level. There was no dose limiting toxicity (DLT) observed in each level. Augmentation of peptide-specific CTL responses in the post-vaccination peripheral blood mononuclear cells was observed in each level, while increased titer of peptide-specific IgG antibodies was observed in the post-vaccination plasma in level 2 and level 3. Applicable responses were no complete response, two partial responses (15%), and 7 stable diseases (55%). Nevertheless 7 patients of them (54%) were under the second-line chemotherapy, disease control rate was 70%, the median TTP (time to progression) was 18.5 weeks and the MST (median survival time) was 7.6 months in this study. Conclusions: The combination therapy of personalized peptide vaccination with GEM for APC patients is feasible and safe. Because of positive immune responses under a full dose of GEM, the peptide vaccination of 3 mg is recommended. No significant financial relationships to disclose.
The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study
Authors: Anil Tombak, Naci Tiftik, Mehmet Hilmi Dogu, Ismail Sari, Meltem Olga Akay, Mustafa Karagulle, Emin Kaya, Serdal Korkmaz, Mehmet Sencan, Gulsah Akyol, Leylagul Kaynar, Melda Comert, Guray Saydam, Sinan Mehmet Dal, Orhan M. Ayyildiz, Rahsan Yildirim, Ilhami Kiki, Erdal Kara, Ramazan Esen, Mehmet Ali Sungur, Mehmet Ali Erkurt, Fevzi Altuntas, Ali Unal, Osman Ilhan
Journal: Blood (2014)
Bone regeneration induced by a 3D architectured hydrogel in a rat critical-size calvarial defect
Authors: P. Lohmann, A. Willuweit, A.T. Neffe, S. Geisler, T.P. Gebauer, S. Beer, H.H. Coenen, H. Fischer, B. Hermanns-Sachweh, A. Lendlein, N.J. Shah, F. Kiessling, K.-J. Langen
Journal: Biomaterials (2016)